Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago.
The company reported that in heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level and that lacutamab was well-tolerated with a safety profile consistent with prior studies.
Dr. Sonia Quaratino, CMO of Innate Pharma, said, “These results are very promising, considering the number of prior systemic therapies that the patients had received before, and the lack of available drugs. These data support further development of lacutamab to bring improved treatments to patients with cutaneous T cell lymphomas.”
Innate Pharma is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients.
